Medicina
Facultad
Vita-Salute San Raffaele University
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Vita-Salute San Raffaele University (19)
2024
2023
-
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity
Journal of Allergy and Clinical Immunology, Vol. 152, Núm. 4, pp. 984-996.e10
-
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
Leukemia, Vol. 37, Núm. 7, pp. 1521-1529
-
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176
-
Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
HemaSphere
-
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
Genome Medicine, Vol. 15, Núm. 1
-
Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo
Molecular Therapy - Methods and Clinical Development, Vol. 30, pp. 546-557
-
Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T-cells for the treatment of Hyper IgM1
EMBO Journal, Vol. 42, Núm. 23
2022
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846
-
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia
2021
-
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study
Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 2, pp. 520-531
-
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Journal of Neurology, Vol. 268, Núm. 11, pp. 3961-3968
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
European Journal of Immunology, Vol. 51, Núm. 12, pp. 2708-3145
-
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
Science immunology, Vol. 6, Núm. 62
2020
2016
2010
-
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies
The Lancet, Vol. 375, Núm. 9733, pp. 2215-2222
2008
-
72-Hour epidural infusion of 0.125% levobupivacaine following total knee replacement: A prospective, randomized, controlled,multicenter evaluation
Acta Biomedica de l'Ateneo Parmense, Vol. 79, Núm. 1, pp. 28-35